The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of safety, pharmacokinetics, and efficacy of TSU-68 plus S-1 combination in patients with advanced hepatocellular carcinoma.
Masafumi Ikeda
Honoraria - Taiho Pharmaceutical; Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical; Taiho Pharmaceutical
Shuichiro Shiina
No relevant relationships to disclose
Kohei Nakachi
No relevant relationships to disclose
Shuichi Mitsunaga
No relevant relationships to disclose
Satoshi Shimizu
No relevant relationships to disclose
Yasushi Kojima
No relevant relationships to disclose
Hideki Ueno
Honoraria - Taiho Pharmaceutical; Taiho Pharmaceutical
Chigusa Morizane
No relevant relationships to disclose
Shunsuke Kondo
No relevant relationships to disclose
Yasunari Sakamoto
No relevant relationships to disclose
Ryosuke Tateishi
No relevant relationships to disclose
Yoshinari Asaoka
No relevant relationships to disclose
Kazuhiko Koike
No relevant relationships to disclose
Hitoshi Arioka
Honoraria - Taiho Pharmaceutical
Takuji Okusaka
Honoraria - Taiho Pharmaceutical; Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical; Taiho Pharmaceutical